Images

Filter by

Table 2 Example Digital Programmes or Treatments Aimed at Patients with Type 2 Diabetes
Table 2: Example Digital Programmes or Treatments Aimed at Patients with Type 2 Diabetes
Table 1 General Digital Therapeutics Features as Applied to Type 2 Diabetes
Table 1: General Digital Therapeutics Features as Applied to Type 2 Diabetes
Figure 3 Clinical Outcomes in Different Groups of Acute Heart Failure Patients
Figure 3: Clinical Outcomes in Different Groups of Acute Heart Failure Patients
Table 2 Cox Regression Analysis of 1 Year Mortality in Acute Heart Failure Patients Stratified by Prognostic Nutritional Index and BMI
Table 2: Cox Regression Analysis of 1-Year Mortality in Acute Heart Failure Patients Stratified by Prognostic Nutritional Index and BMI
Figure 2 Continued
Figure 2: Continued
Figure 2 One year Survival Analysis of Different Groups of Acute Heart Failure Patients
Figure 2: One-year Survival Analysis of Different Groups of Acute Heart Failure Patients
Figure 1 Kaplan–Meier Survival Curves for 1 Year Mortality for Acute Heart Failure Patients Stratified by Prognostic Nutritional Index or BMI
Figure 1: Kaplan–Meier Survival Curves for 1-Year Mortality for Acute Heart Failure Patients Stratified by Prognostic Nutritional Index or BMI
Table 1 Baseline Characteristics of the Study Population Stratified by Prognostic Nutritional Index
Table 1: Baseline Characteristics of the Study Population Stratified by Prognostic Nutritional Index
Figure 2 Cumulative Mortality Rates Matched for Cardiac Rehabilitation Use
Figure 2: Cumulative Mortality Rates Matched for Cardiac Rehabilitation Use
Figure 1 Dietary Intervention for Cardiovascular Health Based on Current Evidence
Figure 1: Dietary Intervention for Cardiovascular Health Based on Current Evidence
Figure 2 Landmark Clinical Trials on Finerenone in Relation to Left Ventricular Ejection Fraction Spectrum
Figure 2: Landmark Clinical Trials on Finerenone in Relation to Left Ventricular Ejection Fraction Spectrum
Table 3 Phase III Clinical Trials of Finerenone on Cardiovascular and Renal Outcomes
Table 3: Phase III Clinical Trials of Finerenone on Cardiovascular and Renal Outcomes